Available Clinical Trials

Clinical Research is an integral part of oncology at Bon Secours Richmond Health System. Clinical trials give patients access to the newest and best treatments for cancer. Bon Secours Richmond Health System is proud to provide the same options as leading national cancer centers. Whether it is looking at new surgical or radiation interventions, or giving a brand new medication, We are striving to find better ways to treat, prevent, and manage cancer.

To inquire about participation in a clinical trial, please contact us at (804) 893-8717.

Please see the available, in-progress clinical trials at Bon Secours Richmond Health System. You may filter these results by searching by disease type or keyword.

Search Clinical Trials

Select Category       or   
Displaying All Clinical Trials (11 - 20 of 47)

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients …

D8531C00002 (CAMBRIA-1)

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy

D926PC00001 Tropion-Breast02

A Study of Dato-DXd Versus Investigator’s Choice Chemotherapy in Patients with Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, who …


EA1151 Tomosynthesis Mammographic Imaging Screening Trial (TMIST)


A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with …


Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with …


Mobile Health for Adherence in Breast Cancer Patients


(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response


A Randomized, Phase II Trial of Cabozatinib and Cabozaninib plus Nivolumab vs Standard Chemotherapy in Patients with previously treated NSCLC


NCI‐Molecular Analysis For Therapy Choice Program (NCI‐ MATCH)